Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | SELP | P16109 | 9/20 | 0.54 |
| ▸ | SELL | P14151 | 3/20 | 0.52 |
| ▸ | SELE | P16581 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CETP | P11597 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22658273 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658269 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658274 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL21537086 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL24777275 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658272 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL24777277 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658271 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL23957944 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658268 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1594 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694924-A2 | METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING VACCINES | Rock Biomedical Inc. (TW) | 2026-02-18 | — | — | EP | claimed |
| US-20260041764-A1 | EXTRACELLULAR VESICLES FOR VACCINE DELIVERY | LONZA SALES AG (CH) | 2026-02-12 | — | — | US | claimed |
| US-20260035479-A1 | GD2 BI-SPECIFIC INVARIANT NATURAL KILLER T CELL ENGAGERS AND METHODS OF USE THEREOF | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-02-05 | — | — | US | claimed |
| US-12453761-B2 | Treatment and detection of infection and disease associated with different fungal pathogens | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2025-10-28 | — | — | US | claimed |
| US-20250326839-A1 | TREATMENT OF DISEASES RELATED TO COLONY-STIMULATING FACTOR 1 RECEPTOR DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE INC (US) | 2025-10-23 | — | — | US | claimed |
| US-20250327029-A1 | PROCESS FOR THE OBTENTION OF INVARIANT NATURAL KILLER T CELLS | UNIVERSITÉ DE LORRAINE (FR) | 2025-10-23 | — | — | US | claimed |
| EP-4619024-A1 | COMPOSITIONS AND METHODS OF MAIT CELL ACTIVATION | ImmunityBio, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-12414968-B2 | Compositions comprising bacterially derived minicells and methods of using the same | ENGENEIC MOLECULAR DELIVERY PTY LTD (AU) | 2025-09-16 | — | — | US | claimed |
| US-20250282866-A1 | TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE INC (US) | 2025-09-11 | — | — | US | claimed |
| US-20250269001-A1 | METHODS TO STIMULATE IMMUNE RESPONSES TO MUTANT RAS USING ANUCLEATE CELLS | STEMCELL TECHNOLOGIES CANADA INC. (CA) | 2025-08-28 | — | — | US | claimed |
| EP-0650732-B1 | NOVEL MEDICINAL COMPOSITION | KIRIN BREWERY (JP) | 2001-04-04 | — | — | EP | claimed |
| EP-1018548-A1 | CELLULAR IMMUNOGENICITY POTENTIATING COMPOSITION CONTAINING $g(a)-GLYCOSYLCERAMIDE | KIRIN BEER KABUSHIKI KAISHA (JP) | 2000-07-12 | — | — | EP | claimed |
| EP-1016409-A1 | FREEZE-DRIED COMPOSITION CONTAINING GLYCOSPHINGOLIPID AND PROCESS FOR PRODUCING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2000-07-05 | — | — | EP | claimed |
| US-6071884-A | ADMINISTERING TO THE PATIENT ATLEAST ONE ALPHA-GALACTOSYLCERAMIDE TO TREAT THROMBOCYTOPENIA | KIRIN BEER KABUSHIKI KAISHA (JP) | 2000-06-06 | — | — | US | claimed |
| EP-0988860-A1 | NKT CELL ACTIVATORS CONTAINING $g(a)-GLYCOSYLCERAMIDES | KIRIN BEER KABUSHIKI KAISHA (JP) | 2000-03-29 | — | — | EP | claimed |
| US-6017892-A | Method for accelerating marrow cell proliferation | KIRAN BEER KABUSHIKI KAISHA (JP) | 2000-01-25 | — | — | US | claimed |
| EP-0957161-A1 | METHOD FOR ACTIVATING HUMAN ANTIGEN PRESENTING CELLS, ACTIVATED HUMAN ANTIGEN PRESENTING CELLS, AND USE OF THE SAME | Kirin Brewery Company, Ltd. (JP) | 1999-11-17 | — | — | EP | claimed |
| US-5936076-A | ANTITUMOR/ANTICARCINOGENIC AGENTS; IMMUNOSTIMULATORS; THERAPY AGAINST INFECTIONS, AQUIRED IMMUNE DEFICIENCY SYNDROME | KIRIN BEER KABUSHIKI KAISHA (JP) | 1999-08-10 | — | — | US | claimed |
| US-5767092-A | Treatment of radiation-damaged bone marrow using galactosyl ceramides | KIRIN BEER KABUSHIKI KAISHA (JP) | 1998-06-16 | — | — | US | claimed |
| EP-0650732-A1 | NOVEL MEDICINAL COMPOSITION | KIRIN BEER KABUSHIKI KAISHA (JP) | 1995-05-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041764-A1 | EXTRACELLULAR VESICLES FOR VACCINE DELIVERY | EXOSC10, EXOSC5, HLA-DRB1 | APP 1785/4885SELP 421/4885SELL 729/4885 |
| US-20260035479-A1 | GD2 BI-SPECIFIC INVARIANT NATURAL KILLER T CELL ENGAGERS AND METHODS OF USE THEREOF | CD22, IL2RA, B2M | APP 1444/4885SELP 968/4885SELL 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.